Before the pandemic, wearable devices were being used by a huge number of patients to diagnose, treat, and monitor their diseases. According to a study conducted by Mordor Intelligence, the wearable technology market was valued at USD 27.91 billion in 2019 and is expected to reach USD 74.03 billion by 2025, at a CAGR of 17.65 percent the period between 2010 – 2025
Fremont, CA: The COVID-19 pandemic outbreak has led to increased growth in demand for healthcare products like ventilators, face masks, medical clothing, testing kits, and monitoring and diagnostic devices. The increasing demand has led to high expectations from the medical technology industry. The Food and Drug Administration (FDA) guided medical technology makers to help the process of production and distribution become more efficient. According to the FDA, the guidance is aimed to assist manufacturers in providing the agency with informative notifications about changes in the production of specific medical devices that will help the agency prevent or mitigate shortages of such devices during the public health emergency. These devices include remote monitoring technology, which during these times, helps eliminate unnecessary patient contact and ease the burden on hospitals and other healthcare facilities like Nemaura Medical, Abbott Laboratories, Johnson & Johnson, Novavax, and Moderna.
Before the pandemic, wearable devices were being used by an increasing number of patients to diagnose, treat, and monitor their diseases. According to a study conducted by Mordor Intelligence, the wearable technology market was valued at USD 27.91 billion in 2019 and is expected to reach USD 74.03 billion by 2025, at a CAGR of 17.65 percent the period between 2010 – 2025. Recently, Dexcom's partnership with Current Health to add continuous glucose monitoring capabilities to Current Health's AI-powered remote patient monitoring platform has proven useful during the pandemic. The facility is essential and beneficial for diabetic patients who are at a higher risk of becoming infected during the pandemic.
Namaura Medical announced the issue of a presentation outlining how quarantined and hospitalized COVID-19 patients are leveraging CGM. The Company has previously reported continuous lactate measurements for the monitoring of disease progression in COVID-19 patients. The new report outlines how CGM has been used as a useful tool for monitoring disease progression in both quarantined and hospitalized COVID-19 patients. This includes improved glycemic control in persons with Type 2 diabetes, monitoring and managing hyperglycemia in patients with COVID-19, and remote monitoring of glucose levels in hospitalized COVID-19 patients leading to improved quality of care, compromising the safety of medical professionals.
